Omalizumab + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Persistent Allergic Asthma

Conditions

Persistent Allergic Asthma

Trial Timeline

Sep 1, 2010 → Oct 1, 2013

NCT ID

NCT01202903

About Omalizumab + Placebo

Omalizumab + Placebo is a phase 3 stage product being developed by Novartis for Persistent Allergic Asthma. The current trial status is completed. This product is registered under clinical trial identifier NCT01202903. Target conditions include Persistent Allergic Asthma.

What happened to similar drugs?

4 of 7 similar drugs in Persistent Allergic Asthma were approved

Approved (4) Terminated (1) Active (3)

🔄E7777 9 mcg/kgEisaiPhase 3

✅Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved

🔄CertoparinNovartisPhase 3

✅RivastigmineNovartisApproved

✅Omalizumab + PlaceboNovartisApproved

🔄placebo + iv sildenafilPfizerPhase 3

✅irbesartan + placeboSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03369704	Phase 3	Completed	Dec 15, 2017	Oct 20, 2018	Seasonal Allergic Rhinitis
NCT03328897	Phase 3	Completed	Apr 26, 2017	Sep 24, 2019	Chronic Spontaneous Urticaria
NCT01723072	Phase 3	Completed	Jan 23, 2013	May 9, 2014	Chronic Spontaneous Urticaria
NCT01202903	Phase 3	Completed	Sep 1, 2010	Oct 1, 2013	Persistent Allergic Asthma
NCT01007149	Phase 3	Completed	Sep 1, 2009	Feb 1, 2011	Asthma
NCT00870584	Approved	Completed	Mar 1, 2009	Mar 1, 2010	Persistent Allergic Asthma
NCT00657891	Approved	Completed	Mar 1, 2007	Oct 1, 2007	Asthma
NCT00454051	Approved	Completed	Dec 1, 2006	Mar 1, 2008	Asthma
NCT01393340	Phase 2	Completed	Dec 1, 2006	Dec 1, 2009	Nasal Polyposis
NCT00123630	Phase 2	Completed	Nov 1, 2005	Jan 1, 2010	Esophagitis

Competing Products

20 competing products in Persistent Allergic Asthma

See all competitors

Product	Company	Stage	Hype Score
E7777 9 mcg/kg	Eisai	Phase 3	40
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solution	Santen Pharmaceutical	Phase 2	35
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment E	AstraZeneca	Phase 1	29
AZD0837 + VKA INR 2-3	AstraZeneca	Phase 2	35
AZD0837 + Aspirin	AstraZeneca	Phase 2	35
Montelukast to placebo + Placebo to montelukast	Merck	Pre-clinical	26
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone Acetate	Novartis	Phase 2	35
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + Placebo	Novartis	Approved	35
Certoparin	Novartis	Phase 3	40
Rivastigmine	Novartis	Approved	43
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 days	Novartis	Phase 2	35
Indacaterol + Placebo to Indacaterol	Novartis	Phase 2	35
Omalizumab + Placebo	Novartis	Approved	43
placebo + iv sildenafil	Pfizer	Phase 3	40
etanercept + placebo	Pfizer	Phase 2	35
Sildenafil	Pfizer	Phase 2	27
irbesartan + placebo	Sanofi	Approved	39
iloprost	Bayer	Pre-clinical	15
IV Remodulin + Placebo	United Therapeutics	Phase 2	24
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)	Glaukos	Phase 2	24